From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors von Ashkenazi, Avi, Fairbrother, Wayne J., Leverson, Joel D., Souers, Andrew J.

Volltext

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets von Souers, Andrew J, Leverson, Joel D, Boghaert, Erwin R, Ackler, Scott L, Catron, Nathaniel D, Chen, Jun, Dayton, Brian D, Ding, Hong, Enschede, Sari H, Fairbrother, Wayne J, Huang, David C S, Hymowitz, Sarah G, Jin, Sha, Khaw, Seong Lin, Kovar, Peter J, Lam, Lloyd T, Lee, Jackie, Maecker, Heather L, Marsh, Kennan C, Mason, Kylie D, Mitten, Michael J, Nimmer, Paul M, Oleksijew, Anatol, Park, Chang H, Park, Cheol-Min, Phillips, Darren C, Roberts, Andrew W, Sampath, Deepak, Seymour, John F, Smith, Morey L, Sullivan, Gerard M, Tahir, Stephen K, Tse, Chris, Wendt, Michael D, Xiao, Yu, Xue, John C, Zhang, Haichao, Humerickhouse, Rod A, Rosenberg, Saul H, Elmore, Steven W

Volltext

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models von Punnoose, Elizabeth A, Leverson, Joel D, Peale, Franklin, Boghaert, Erwin R, Belmont, Lisa D, Tan, Nguyen, Young, Amy, Mitten, Michael, Ingalla, Ellen, Darbonne, Walter C, Oleksijew, Anatol, Tapang, Paul, Yue, Peng, Oeh, Jason, Lee, Leslie, Maiga, Sophie, Fairbrother, Wayne J, Amiot, Martine, Souers, Andrew J, Sampath, Deepak

Volltext

Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐XL–BAX interaction von Saleh, Tareq, Carpenter, Valerie J., Tyutyunyk‐Massey, Liliya, Murray, Graeme, Leverson, Joel D., Souers, Andrew J., Alotaibi, Moureq R., Faber, Anthony C., Reed, Jason, Harada, Hisashi, Gewirtz, David A.

Volltext

Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax von Leverson, Joel D, Sampath, Deepak, Souers, Andrew J, Rosenberg, Saul H, Fairbrother, Wayne J, Amiot, Martine, Konopleva, Marina, Letai, Anthony

Volltext

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor von Xiao, Yu, Nimmer, Paul, Sheppard, George S, Bruncko, Milan, Hessler, Paul, Lu, Xin, Roberts-Rapp, Lisa, Pappano, William N, Elmore, Steven W, Souers, Andrew J, Leverson, Joel D, Phillips, Darren C

Volltext

Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-X-L-BAX interaction von Saleh, Tareq, Carpenter, Valerie J., Tyutyunyk-Massey, Liliya, Murray, Graeme, Leverson, Joel D., Souers, Andrew J., Alotaibi, Moureq R., Faber, Anthony C., Reed, Jason, Harada, Hisashi, Gewirtz, David A.

Volltext

New era for myelofibrosis treatment with novel agents beyond Janus kinase‐inhibitor monotherapy: Focus on clinical development of BCL‐XL/BCL‐2 inhibition with navitoclax von Pemmaraju, Naveen, Garcia, Jacqueline S, Perkins, Andrew, Harb, Jason G, Souers, Andrew J, Werner, Michael E, Brown, Christopher M, Passamonti, Francesco

Volltext

Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR -Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target von Song, Kyung-A, Hosono, Yasuyuki, Turner, Crystal, Jacob, Sheeba, Lochmann, Timothy L, Murakami, Yoshiko, Patel, Neha U, Ham, Jungoh, Hu, Bin, Powell, Krista M, Coon, Colin M, Windle, Brad E, Oya, Yuko, Koblinski, Jennifer E, Harada, Hisashi, Leverson, Joel D, Souers, Andrew J, Hata, Aaron N, Boikos, Sosipatros, Yatabe, Yasushi, Ebi, Hiromichi, Faber, Anthony C

Volltext

Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression von Lochmann, Timothy L, Floros, Konstantinos V, Naseri, Mitra, Powell, Krista M, Cook, Wade, March, Ryan J, Stein, Giovanna T, Greninger, Patricia, Maves, Yuki Kato, Saunders, Laura R, Dylla, Scott J, Costa, Carlotta, Boikos, Sosipatros A, Leverson, Joel D, Souers, Andrew J, Krystal, Geoffrey W, Harada, Hisashi, Benes, Cyril H, Faber, Anthony C

Volltext

Senolytic-Mediated Elimination of Head and Neck Tumor Cells Induced Into Senescence by Cisplatin von Ahmadinejad, Fereshteh, Bos, Tasia, Hu, Bin, Britt, Erin, Koblinski, Jennifer, Souers, Andrew J, Leverson, Joel D, Faber, Anthony C, Gewirtz, David A, Harada, Hisashi

Volltext

Integrated molecular and functional characterization of the intrinsic apoptotic machinery identifies therapeutic vulnerabilities in glioma von Fernandez, Elizabeth G., Mai, Wilson X., Song, Kai, Bayley, Nicholas A., Kim, Jiyoon, Zhu, Henan, Pioso, Marissa, Young, Pauline, Andrasz, Cassidy L., Cadet, Dimitri, Liau, Linda M., Li, Gang, Yong, William H., Rodriguez, Fausto J., Dixon, Scott J., Souers, Andrew J., Li, Jingyi Jessica, Graeber, Thomas G., Cloughesy, Timothy F., Nathanson, David A.

Volltext

Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein von Petros, Andrew M., Swann, Steven L., Song, Danying, Swinger, Kerren, Park, Chang, Zhang, Haichao, Wendt, Michael D., Kunzer, Aaron R., Souers, Andrew J., Sun, Chaohong

Volltext

A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies von Phillips, Darren C., Jin, Sha, Gregory, Gareth P., Zhang, Qi, Xue, John, Zhao, Xiaoxian, Chen, Jun, Tong, Yunsong, Zhang, Haichao, Smith, Morey, Tahir, Stephen K., Clark, Rick F., Penning, Thomas D., Devlin, Jennifer R., Shortt, Jake, Hsi, Eric D., Albert, Daniel H., Konopleva, Marina, Johnstone, Ricky W., Leverson, Joel D., Souers, Andrew J.

Volltext

Structure-Guided Design of a Series of MCL‑1 Inhibitors with High Affinity and Selectivity von Bruncko, Milan, Wang, Le, Sheppard, George S, Phillips, Darren C, Tahir, Stephen K, Xue, John, Erickson, Scott, Fidanze, Steve, Fry, Elizabeth, Hasvold, Lisa, Jenkins, Gary J, Jin, Sha, Judge, Russell A, Kovar, Peter J, Madar, David, Nimmer, Paul, Park, Chang, Petros, Andrew M, Rosenberg, Saul H, Smith, Morey L, Song, Xiaohong, Sun, Chaohong, Tao, Zhi-Fu, Wang, Xilu, Xiao, Yu, Zhang, Haichao, Tse, Chris, Leverson, Joel D, Elmore, Steven W, Souers, Andrew J

Volltext

MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma von Fu, Dechen, Pfannenstiel, Luke, Demelash, Abeba, Phoon, Yee Peng, Mayell, Cameron, Cabrera, Claudia, Liu, Caini, Zhao, Junjie, Dermawan, Josephine, Patil, Deepa, DeVecchio, Jennifer, Kalady, Matthew, Souers, Andrew J., Phillips, Darren C., Li, Xiaoxia, Gastman, Brian

Volltext

Pharmaceutical Development Challenges in a Beyond Rule of Five Prodrug: Case Study of ABBV-167, Phosphate Prodrug of Venetoclax von Hong, Richard, Nie, Haichen, Henry, Rodger F., Garner, Sean M., Catron, Nathaniel D., Hertzler, Russell L., Souers, Andrew J., Sheikh, Ahmad Y., Chen, Shuang

Volltext

Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells von Bodo, Juraj, Zhao, Xiaoxian, Durkin, Lisa, Souers, Andrew J, Phillips, Darren C, Smith, Mitchell R, Hsi, Eric D

Volltext

Enabling, Decagram-Scale Synthesis of Macrocyclic MCL‑1 Inhibitor ABBV-467 von Brady, Patrick B., Sorensen, Bryan K., Risi, Roberto M., Curtin, Michael L., Mantei, Robert A., Florjancic, Alan S., Mastracchio, Anthony, Ji, Cheng, Kunzer, Aaron R., Lai, Chunqiu, Storer, Gregory E., Chan, Vincent S., Henry, Rodger F., Souers, Andrew J., Michaelides, Michael R., Judd, Andrew S., Hansen, T. Matthew

Volltext

Discovery of a Potent and Selective BCL‑XL Inhibitor with in Vivo Activity von Tao, Zhi-Fu, Hasvold, Lisa, Wang, Le, Wang, Xilu, Petros, Andrew M, Park, Chang H, Boghaert, Erwin R, Catron, Nathaniel D, Chen, Jun, Colman, Peter M, Czabotar, Peter E, Deshayes, Kurt, Fairbrother, Wayne J, Flygare, John A, Hymowitz, Sarah G, Jin, Sha, Judge, Russell A, Koehler, Michael F. T, Kovar, Peter J, Lessene, Guillaume, Mitten, Michael J, Ndubaku, Chudi O, Nimmer, Paul, Purkey, Hans E, Oleksijew, Anatol, Phillips, Darren C, Sleebs, Brad E, Smith, Brian J, Smith, Morey L, Tahir, Stephen K, Watson, Keith G, Xiao, Yu, Xue, John, Zhang, Haichao, Zobel, Kerry, Rosenberg, Saul H, Tse, Chris, Leverson, Joel D, Elmore, Steven W, Souers, Andrew J

Volltext